AMNEAL PHARMACEUTICALS INC (AMRX) Stock News

USA - NASDAQ:AMRX - US03168L1052 - Common Stock

11.64 USD

+0.12 (+1.04%)

Last: 11/14/2025, 5:40:40 PM

11.64 USD

0 (0%)

After Hours: 11/14/2025, 5:40:40 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AMRX Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Chartmill

News Image

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance

10 hours ago - By: Zacks Investment Research - Mentions: TEVA ANIP VTRS

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

a day ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Iohexol Injection

a day ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Iohexol Injection

10 days ago - By: Zacks Investment Research

Implied Volatility Surging for Amneal Pharmaceuticals Stock Options

15 days ago - By: Zacks Investment Research

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

16 days ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

16 days ago - By: Amneal Pharmaceuticals LLC

Amneal Reports Third Quarter 2025 Financial Results

16 days ago - By: Amneal Pharmaceuticals LLC

Amneal Reports Third Quarter 2025 Financial Results

16 days ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

18 days ago - By: Amneal Pharmaceuticals LLC

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

18 days ago - By: Amneal Pharmaceuticals LLC

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

22 days ago - By: Zacks Investment Research - Mentions: UTHR

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

a month ago - By: Benzinga - Mentions: AMPH TEVA RDY VTRS

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

a month ago - By: Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma - Mentions: ALVO

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

a month ago - By: Zacks Investment Research - Mentions: ANIX

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal to Report Third Quarter 2025 Results on October 30, 2025

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal to Report Third Quarter 2025 Results on October 30, 2025

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

2 months ago - By: Stocktwits - Mentions: AGN

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

2 months ago - By: Amneal Pharmaceuticals LLC

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension